Texas Heart Institute Journal · 2014 · 27 citations · 37 references
MedicineCardiologyInternal MedicineCardiovascular PharmacotherapyClinical CardiologyDrug Utilization ReviewCardiac MedicationsCardiovascular DiseaseHeart FailureHypertension ManagementIschemic Heart DiseaseAmbulatory Care UseAngiotensin Ii Receptor BlockersAngiotensin-converting Enzyme Inhibitor ManagementBeta-adrenergic Blocker UseBeta-blocker UseChronic Heart Failure ManagementCongestive Heart Failure ManagementHeart Failure Epidemiology
Better outpatient management of heart failure might improve outcomes and reduce the number of rehospitalizations. This study describes recent outpatient heart-failure management in the United States. We analyzed data from the National Ambulatory Medical Care Survey of 2006-2008, a multistage random sampling of non-Federal physician offices and hospital outpatient departments. Annually, 1.7% of all outpatient visits were for heart failure (51% females and 77% non-Hispanic whites; mean age, 73 ± 0.5 yr). Typical comorbidities were hypertension (62%), hyperlipidemia (36%), diabetes mellitus (35%), and ischemic heart disease (29%). Body weight and blood pressure were recorded in about 80% of visits, and health education was given in about 40%. The percentage of patients taking β-blockers was 38%; the percentage taking angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) was 32%. Medication usage did not differ significantly by race or sex. In multivariate-adjusted logistic regression models, a visit to a cardiologist, hypertension, heart failure as a primary reason for the visit, and a visit duration longer than 15 minutes were positively associated with ACEI/ARB use; and a visit to a cardiologist, heart failure as a primary reason for the visit, the presence of ischemic heart disease, and visit duration longer than 15 minutes were positively associated with β-blocker use. Chronic obstructive pulmonary disease was negatively associated with β-blocker use. Approximately 1% of heart-failure visits resulted in hospitalization. In outpatient heart-failure management, gaps that might warrant attention include suboptimal health education and low usage rates of medications, specifically ACEI/ARBs and β-blockers.
37
2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Journal of the American College of Cardiology · 2013 · 12.6K citations
Heart Disease and Stroke Statistics—2011 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2010 · 6.2K citations
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet · 1999 · 4.9K citations
Medicine, Cardiology, Pharmacology +10
Effect of Carvedilol on Survival in Severe Chronic Heart Failure
Milton Packer, Andrew J.S. Coats, Michael B. Fowler et al. · New England Journal of Medicine · 2001 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +11